Nuwellis (NUWE) shares more than doubled in recent Monday trading after the Centers for Medicare and Medicaid Services almost quintupled the reimbursement rate for the company's Aduadex SmartFlow therapy, effective Jan. 1.
The (CMS) "will reassign the Aquadex ultrafiltration code to the outpatient reimbursement level most consistent with administration of ultrafiltration therapy and cost of treatment" with the payment rate increasing to $1,639 a day from $413, Nuwellis said Monday in a statement.
The reassignment recognizes the effectiveness of the therapy for the treatment of fluid overload in heart failure patients.
Price: 2.98, Change: +1.62, Percent Change: +119.26
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。